MAIA Biotechnology, Inc.
MAIA- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001878313
In the last 90 days, MAIA Biotechnology, Inc. insiders filed 5 open-market purchases and 0 sales; 36 institutions reported holding it in 13F filings for Q2 2026, worth $19.4M in total; no superinvestor holds it.
Q2 2023 vs. Q1 2023
How the institutions holding MAIA Biotechnology, Inc. changed between Q1 2023 and Q2 2023.
All holders in Q2 2023All holders in Q1 2023
| Measure | Q1 2023 | Q2 2023 | Change |
|---|---|---|---|
| Holders | 6 | 12 | +6 |
| Shares | 71.5K | 321.9K | +250.4K (+350.1%) |
| Value | $246.7K | $709.1K | +$462.4K (+187.4%) |
New holders (7)
Institutions that held MAIA Biotechnology, Inc. at the end of Q2 2023 but not at the end of Q1 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Vanguard Group Inc | 93,500 | $205.7K | 0.00% |
| Lynwood Capital Management Inc. | 35,000 | $77.0K | 0.10% |
| Geode Capital Management, LLC | 33,987 | $74.8K | 0.00% |
| Bridgeway Capital Management, LLC | 26,600 | $58.5K | 0.00% |
| Citadel Advisors LLC | 23,387 | $51.5K | 0.00% |
| Naviter Wealth, LLC | 22,168 | $48.8K | 0.01% |
| Royal Bank of Canada | 27 | $0 | 0.00% |
Sold out (1)
Institutions that held MAIA Biotechnology, Inc. at the end of Q1 2023 and filed for Q2 2023 without it.
| Institution | Shares, Q1 2023 | Value, Q1 2023 |
|---|---|---|
| UBS Group AG | 3,949 | $13.7K |